J. Spoerke

发表

A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.

Steven J. Schrodi, Annette Lee, P. Gregersen, 2004, American journal of human genetics.

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

J. Ware, J. Spoerke, P. Workman, 2014, Clinical Cancer Research.

High-throughput isolation of Caenorhabditis elegans deletion mutants.

B Reardon, Leo X. Liu, Evan L. Mulligan, 1999, Genome research.

TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer

Ru-Fang Yeh, Richard Bourgon, Zachary Boyd, 2011, Science Signaling.

Erratum: EGO-1 is related to RNA-directed RNA polymerase and functions in germ-line development and RNA interference in C. elegans (Current Biology (2000) 10 (169-178))

Anne M. Smardon, J. Spoerke, Nancy A. Mackin, 2000 .

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

DIFFERENTIAL RESPONSES OF GROWTH AND TWO SOLUBLE PHENOLICS OF TOMATO TO RESOURCE AVAILABILITY

Nancy E. Stamp, J. Spoerke, N. Stamp, 1996 .

Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort

May M. Y. Liang-Chu, Mamie Yu, J. Spoerke, 2019, Clinical Cancer Research.

Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results

M. Ellis, E. Winer, E. Perez, 2015 .

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.

J. Ware, J. Spoerke, J. Schellens, 2017, The oncologist.

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Carlos L. Arteaga, H. Linden, A. Bardia, 2022, Breast Cancer Research and Treatment.

om92 , a glp-1 enhancer mutation, is an allele of ekl-1

K. O’Connell, J. Spoerke, Harold E. Smith, 2022, microPublication biology.

A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)

Yulei N. Wang, J. Ware, J. Spoerke, 2016, Cancer.

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

L. Honigberg, J. Spoerke, D. Jeffery, 2007, ChemMedChem.

J. Spoerke, Nancy A. Mackin, A. Smardon, 2000, Current Biology.

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

M. Belvin, J. Spoerke, D. Sutherlin, 2011, Molecular Cancer Therapeutics.

GDC-0980IsaNovelClassIPI3K/mTORKinaseInhibitorwith RobustActivityinCancerModelsDrivenbythePI3KPathway

M. Belvin, J. Spoerke, D. Sutherlin, 2011 .

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Doron Lipson, Bernard Fendler, Jeffrey P. Gregg, 2018, The Journal of molecular diagnostics : JMD.

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

G. Hampton, Yulei N. Wang, T. Wilson, 2013, Oncogenesis.

Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers

R. Bourgon, T. Wilson, A. Daemen, 2018, Molecular Cancer Research.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

G. Hampton, J. Fridlyand, T. Wilson, 2016, npj Breast Cancer.

Molecular Biomarker Analyses Using Circulating Tumor Cells

Ru-Fang Yeh, Bernard M. Fine, R. Yeh, 2010, PloS one.

miR-221/222 Targeting of Trichorhinophalangeal 1 (TRPS1) Promotes Epithelial-to-Mesenchymal Transition in Breast Cancer

R. Bourgon, R. Yeh, A. Adai, 2011, Science Signaling.

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2018, Breast Cancer Research.

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

G. Hampton, J. Fridlyand, J. Spoerke, 2012, Clinical Cancer Research.

Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.

G. Hampton, K. Walter, J. Spoerke, 2016, Cancer research.

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

A. Ravaud, Yulei N. Wang, R. Motzer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays

Yibing Yan, Carol O'Brien, J. Spoerke, 2008, Molecular Cancer Therapeutics.

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

G. Hampton, K. Walter, T. Wilson, 2016, Nature Communications.

Genomic Analysis of Circulating Tumor Cells at the Single-Cell Level

Yulei N. Wang, W. Xiao, J. Spoerke, 2020, The Journal of molecular diagnostics : JMD.

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Wei Zhou, William F. Forrest, Sherry Heldens, 2012, Molecular Cancer Therapeutics.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

G. Hampton, J. Fridlyand, T. Wilson, 2014, Breast Cancer Research and Treatment.

NONRANDOM GENOTYPIC ASSOCIATIONS IN A LEGUME—BRADYRHIZOBIUM MUTUALISM

J. Spoerke, H. Wilkinson, M. Parker, 1996, Evolution; international journal of organic evolution.

DIVERGENCE IN SYMBIOTIC COMPATIBILITY IN A LEGUME‐BRADYRHIZOBIUM MUTUALISM

J. Spoerke, H. Wilkinson, M. Parker, 1996, Evolution; international journal of organic evolution.

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

G. Hampton, T. Wilson, J. Spoerke, 2014, PloS one.

Abstract P5-19-10: Tolerability and anti-tumor activity of the oral PI3K inhibitor GDC-0941 in combination with paclitaxel, with and without bevacizumab or trastuzumab in patients with locally recurrent or metastatic breast cancer

E. Winer, K. Morrissey, J. Spoerke, 2015 .

Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.

Yulei N. Wang, J. Spoerke, H. Koeppen, 2014 .

Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer

E. Winer, S. Loi, A. Bardia, 2020, Poster Spotlight Session Abstracts.

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

A. Bardia, J. Spoerke, J. Giltnane, 2018 .

A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).

A. Ravaud, T. Powles, R. Motzer, 2014 .

156PDTargeted NGS profiling identifies genomic alterations associated with high-risk eBC

R. Bourgon, T. Wilson, A. Daemen, 2017 .

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

G. Hampton, J. Fridlyand, J. Spoerke, 2012, Clinical Cancer Research.

NONRANDOM GENOTYPIC ASSOCIATIONS IN A LEGUME—BRADYRHIZOBIUM MUTUALISM

J. Spoerke, H. Wilkinson, M. Parker, 1996, Evolution; international journal of organic evolution.

Geographic structure of lineage associations in a plant‐bacterial mutualism

J. Spoerke, M. Parker, 1998 .